Ongoing Clinical Trials for Peripheral Spondyloarthritis
Currently, there is 1 ongoing clinical trial investigating treatment strategies for peripheral spondyloarthritis, a type of inflammatory arthritis that primarily affects the joints in the arms and legs. This trial is comparing early biological treatment with conventional medications to determine the most effective approach for achieving remission in adults with this condition.
Clinical trial locations
Study on Peripheral Spondyloarthritis: Comparing Methotrexate Disodium and Golimumab for Early Remission in Adult Patients
This clinical trial is being conducted in Belgium and focuses on finding the most effective treatment strategy for adults with peripheral spondyloarthritis. The study compares two different approaches: starting with conventional medications versus introducing biological treatment early in the disease course.
Main inclusion criteria:
- Adults between 18 and 65 years of age
- Diagnosed with peripheral spondyloarthritis meeting ASAS classification criteria, which means having current arthritis in the legs, enthesitis (pain where tendons attach to bone), or dactylitis (swelling of fingers or toes) along with at least one feature of spondyloarthritis
- Symptoms that started within the last 12 months before joining the study
- Active disease with a Patient Global Assessment of Disease Activity score of 4 or higher and a Patient Global Assessment of Pain score of 4 or higher
- If spine symptoms are present, the joint symptoms in the arms and legs must be the main concern
Main exclusion criteria:
- Having a different condition than peripheral spondyloarthritis
- Being outside the specified age range
- Being part of a vulnerable population
Focus and goal of the trial:
The study compares two treatment strategies over a period of up to 36 weeks. The first approach, called the csDMARD Step-Up strategy, starts with conventional synthetic disease-modifying drugs like methotrexate or sulphasalazine, which are taken as tablets. The second approach, called the TNFi Induction strategy, introduces biological treatment early using golimumab, which is given as an injection under the skin.
Participants are randomly assigned to one of these two treatment groups. Throughout the study, regular monitoring takes place at baseline, week 12, and week 24, with additional monitoring until week 36 for those continuing treatment. Researchers evaluate various aspects of health, including joint pain and swelling, overall disease activity, and any side effects. The primary goal is to determine which treatment strategy is more effective in helping patients achieve clinical remission, meaning their symptoms are significantly reduced or absent.
Investigational drugs:
The trial uses three main medications. Methotrexate is a conventional synthetic disease-modifying drug that works by slowing down the immune system and reducing inflammation. Sulphasalazine is another conventional medication that helps reduce pain and swelling by affecting the immune system. Golimumab is a biological medication that blocks a protein called Tumor Necrosis Factor (TNF), which plays a key role in inflammation. Golimumab is administered as an injection under the skin and is already used in clinical practice for treating inflammatory conditions.
Summary
Currently, one clinical trial is actively recruiting patients with peripheral spondyloarthritis in Belgium. This study represents an important effort to determine the optimal timing and type of treatment for this condition. The trial specifically focuses on comparing early biological intervention with golimumab against the conventional step-up approach using methotrexate and sulphasalazine.
The study is particularly relevant for patients whose symptoms have appeared recently (within the last 12 months), as it aims to identify whether early aggressive treatment with biological medications can lead to better outcomes compared to starting with traditional medications. The trial is expected to conclude in May 2025 and will provide valuable insights into treatment strategies for adults living with this form of inflammatory arthritis.
